Compare NBIX & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | RDY |
|---|---|---|
| Founded | 1992 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 11.6B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | RDY |
|---|---|---|
| Price | $151.98 | $14.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 1 |
| Target Price | ★ $172.33 | $16.90 |
| AVG Volume (30 Days) | ★ 1.1M | 998.5K |
| Earning Date | 10-28-2025 | 10-24-2025 |
| Dividend Yield | N/A | ★ 0.51% |
| EPS Growth | ★ 12.44 | 9.95 |
| EPS | ★ 4.19 | 0.79 |
| Revenue | $2,682,700,000.00 | ★ $3,851,623,984.00 |
| Revenue This Year | $23.68 | $6.29 |
| Revenue Next Year | $18.02 | $2.61 |
| P/E Ratio | $36.30 | ★ $17.76 |
| Revenue Growth | ★ 19.61 | 14.10 |
| 52 Week Low | $84.23 | $12.26 |
| 52 Week High | $157.67 | $16.17 |
| Indicator | NBIX | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 61.79 | 52.85 |
| Support Level | $139.27 | $13.64 |
| Resistance Level | $144.83 | $14.10 |
| Average True Range (ATR) | 4.59 | 0.19 |
| MACD | 0.49 | 0.04 |
| Stochastic Oscillator | 88.14 | 87.88 |
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.